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Abstract
Introduction: Status dystonicus is a rare but life-threatening disorder characterized by increasingly frequent and
severe episodes of generalized dystonia that may occur in patients with primary or secondary dystonia. Painful and
repetitive spasms interfere with respiration and may cause metabolic disturbances such as hyperpyrexia,
dehydration, respiratory insufficiency, and acute renal failure secondary to rhabdomyolysis. Intrathecally
administered baclofen, delivered by an implantable pump system, is widely used for the treatment of refractory
spasticity. Abrupt cessation of intrathecal baclofen infusion has been associated with a severe withdrawal syndrome
comprised of dystonia, autonomic dysfunction, hyperthermia, end-organ failure and sometimes death. The
aetiology of this syndrome is not well understood. Status dystonicus describes the episodes of acute and life-
threatening generalized dystonia, which occasionally manifest themselves in patients with dystonic syndromes.
Case presentation: We present the case of a nine-year-old Caucasian boy who experienced a severe episode of
status dystonicus with no known cause and clinical features resembling those described in intrathecal baclofen
withdrawal. Our patient subsequently underwent the placement of an intrathecal baclofen pump without incident.
Conclusion: The similarity between the clinical features of the case we present and those reported in connection
to abrupt withdrawal of intrathecal baclofen is emphasized. Several drugs, although not intrathecal baclofen
withdrawal, have previously been associated with status dystonicus. The similarity between the life-threatening
dystonic episode experienced by our patient, and those reported in intrathecal baclofen withdrawal, highlights the
possibility that, rather than representing a true physiological withdrawal syndrome, abrupt withdrawal of intrathecal
baclofen may simply precipitate an episode of status dystonicus in susceptible individuals. The clinical similarities
between the intrathecal baclofen withdrawal syndrome and status dystonicus have not previously been
highlighted.
Introduction
Status Dystonicus (SD) is a rare but life-threatening dis-
order characterized by increasingly frequent and severe
episodes of generalized dystonia that may occur in
patients with primary or secondary dystonia. Painful and
repetitive spasms interfere with respiration and may
cause metabolic disturbances such as hyperpyrexia,
dehydration, respiratory insufficiency, and acute renal
failure secondary to rhabdomyolysis. It is common for a
single patient to experience multiple bouts of SD.
Episodes of SD may be precipitated by infection,
surgery, stress or changes in medication but frequently
no cause is identified. A patient with SD is best mana-
ged with sedation and may require intubation and venti-
lation in severe cases [1].
Intrathecal baclofen (ITB) has been used extensively
for the management of the spasticity that results from a
number of spinal and supra-sp i n a ln e u r o l o g i c a ld i s o r -
ders. ITB is delivered directly to the intrathecal cere-
brospinal fluid (CSF) via a variable rate implantable
pump system, most commonly via a catheter placed in
the lumbar spine; but thoracic and cervical levels can
also be used. When compared with oral dosing, the
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tions with a diminished side-effect profile.
The most common complications observed with the
use of ITB are related to infection, programming errors
and catheter migration or fracture. Abrupt withdrawal
from ITB has been associated with a constellation of
clinical sequalae including pruritus, hyperthermia, con-
fusion, and haemodynamic instability progressing to
rhabdomyolysis, disseminated intravascular coagulation,
multi-end organ failure and, ultimately, death [2-5].
Numerous reports are described in the literature and
the term ‘ITB withdrawal syndrome’ has been used to
define them. Comparisons have been drawn between
ITB withdrawal syndrome and other acute, life-threaten-
ing systemic conditions such as neuroleptic malignant
syndrome, malignant hyperthermia and serotonergic
syndromes [6-8].
Whether the clinical features observed are the result
o fat r u ew i t h d r a w a ls y n d r o m er e p r e s e n t i n gp h y s i o l o g i -
cal dependence is not clear. Often the diagnosis is made
in the context of multiple co-morbidities, when treat-
ment for other acute diagnoses, such as sepsis, has com-
menced. The ability to measure ITB concentrations is
usually not available to give evidence to the proposed
cause of the clinical episode.
We report the case of a patient experiencing an acute
episode of SD with clinical features comparable to those
described in ITB withdrawal. This patient has subse-
quently been fitted with an ITB pump. We compare the
features of this patient’s episode of SD with those of the
previously reported paediatric cases of ITB withdrawal
and discuss the implications for the diagnosis and signif-
icance of complications due to abrupt ITB withdrawal.
Case presentation
A previously well nine-year-old Caucasian boy was
admitted to the Paediatric Int e n s i v eC a r eU n i t( P I C U )
after having a severe hypoxic brain injury following a
near hanging. Recovery was complicated by recurrent,
persistent dystonic extensor spasms. Magnetic resonance
imaging (MRI) six days after admission showed wide-
spread infarction in the watershed areas of both hemi-
spheres and abnormal signal changes within the thalami.
Bouts of spasticity were associated with tachycardia, pyr-
exia and hypoxia. An EEG did not demonstrate an asso-
ciation with cortical activity. Two weeks after admission
our patient was discharged to the general ward, apyrex-
ial and normotensive with normal inflammatory markers
and measures of renal and hepatic function. His GCS
was 5. His medications included lorazepam 1.3 mg PO/
IV QDS, baclofen 20 mg PO TDS, chloral hydrate 1 g
QDS and paracetamol 390 mg PO/PR QDS (his weight
was 26 kg).
Five days after discharge from PICU he was noted to
have a temperature of 39.5°C. Nystatin (100,000 QDS)
was started for oral candida but no other source of
infection was clinically identified. Blood cultures were
negative and C-Reactive Protein (CRP) was 2.8 mg/L.
Routine haematology and tests of renal and hepatic
function were unremarkable apart from an elevation of
aspartate transaminase (175 IU/L).
Our patient continued to deteriorate over the next
24 hours, becoming more agitated and experiencing epi-
sodes of haematemesis. Lorazepam was increased to
2 mg PO/IV QDS and chloral hydrate to 1.3 g QDS.
Ranitidine (75 mg BD) was also started. He remained
cardiovascularly stable (respiratory rate 20 rpm; heart
rate 132 bpm; blood pressure 114/75 mmHg) but
experienced progressive hypoxia and continued spasti-
city. Trihexyphenidyl (0.5 mg BD) was started.
Spasticity, fever (up to 40.4°C), and hypoxia (88% oxy-
gen saturations) accompanied by haematemesis and
diarrhoea continued over the next six days. The patient
became tachycardic, tachypnoeic and hypotensive
(respiratory rate 28 bpm; heart rate 190 bpm; blood
pressure 110/40 mmHg) Chest radiographs excluded a
chest infection and there was no evidence of urinary
tract infection on urine analysis. There was still no
elevation of CRP.
Eight days after the start of this episode the patient
developed a cough and his CRP was found to be ele-
vated (14.4 mg/L). Broad-spectrum antibiotics were
started for a presumed lower respiratory tract infection.
Extensor posturing and hyperpyrexia continued and the
patient was noted as having spasmodic hypertensive epi-
s o d e s .H i su r i n ew a sa l s on o t e dt ob ev e r yd a r ka n d
nine days after the start of the episode his serum crea-
tine kinase (CK) was found to be 55,869 IU/L. His fluids
were changed to a bicarbonate drip of 2 mmol/kg of
NaHCO3 per day.
Over the next few days, our patient became apyrexial
and episodes of dystonia became less frequent. Serum
CK started to fall. Liver function tests, however, were
noted to be deranged (Alanine aminotransferase 621 IU/
L; Aspartate transaminase 411 IU/L; Albumin 30 g/L).
Screening for inbuilt errors of metabolism revealed no
abnormalities. The patient’s condition steadily improved
and, although he continued to have exacerbations of
spasticity, he did not experience another dystonic crisis
of similar severity. He was finally discharged from hospi-
tal nine months after his first admission. Seven months
after his hypoxic injury, the patient underwent elective
placement of a programmable pump device for continu-
ous ITB with good result. At a five-month follow-up he
weighed 35.9 kg with an intrathecal baclofen infusion of
100 micrograms per day. He was also prescribed
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continued to have a good response to the ITB.
Discussion
Infection, surgery, stress and the introduction or with-
drawal of drugs have previously been linked to precipi-
tating SD, although often no precipitating factor is
identified [9]. In our patient SD may have been precipi-
tated by the introduction of any of the new medications
that were started or a withdrawal episode due to emesis.
However, one of the medications taken by this patient
has previously been linked to SD. However, the intro-
duction of benzodiazepines (although not specifically
lorazepam) has been linked to SD. Withdrawal from
long-term oral baclofen is less severe than withdrawal
from intrathecal baclofen but has been linked to a SD-
like syndrome of spasticity and fever. However, the fact
that this patient had only been started on oral baclofen
relatively recently and that emesis did not precede his
agitation and pyrexia militate against oral baclofen with-
drawal being the cause of status dystonicus in this
case [10].
Rhabdomyolysis, as seen in our patient, is a common
complication of SD, owing to intense muscle activity
[11]. During admission, our patient’s pyrexia was attrib-
uted to hypothalamic failure. However, pyrexia regularly
occurs in SD [1,11] due to the massive exothermic
effects of prolonged muscle contraction. Occasionally
SD can lead to multi-organ failure and even death.
Given that our patient subsequently had an ITB pump
fitted, it is notable that the clinical features of his epi-
sode of SD were comparable to those that have been
attributed to ITB withdrawal. A literature review identi-
fied nine previously reported episodes of ITB withdrawal
in the paediatric population and they are summarized in
Table 1.
The five most commonly reported clinical features of
ITB withdrawal (dystonia, pyrexia, tachycardia, agitation,
hypertension) all occurred in our patient. Rhabdomyoly-
sis was a feature of three of the nine extant reports of
complications attributed to ITB withdrawal.
The similarity between the case we report and the
previously reported cases of complications attributed to
ITB withdrawal raises two important points.
Table 1 Summary of reported cases of ITB withdrawal
Author/
Reference
Patient and Primary
Diagnosis
Reason for ITB
failure
Features Reported (those in italics
were not a feature of the case we
report)
Management and Outcome
Hansen et al.
[12]
11 F Cerebral Palsy Removal of infected
ITB Pump several
hours previously
Dystonia, Pyrexia, Rhabdomyolysis,
Tachycardia, Hypertension, Reduced O2
Saturation, Diaphoresis
Admitted to ICU and continuously
sedated. Oral baclofen, dantrium,
cyproheptadine, propofol and clonidine.
Pump replaced with good result.
Samson-
Fang et al.
[7]
9 M Cerebral Palsy Disconnection of
distal tubing from
proximal segment.
Time to onset
unknown.
Dystonia, Pyrexia (39.5°C),
Rhabdomyolysis (15,200 IU/L), Agitation,
Hypertension, Seizure, Scrotal and Ankle
Oedema, Clotting Derangement, Metabolic
Acidosis, Transaminase Elevation,
Leukocytosis, Renal Failure
Oral baclofen and clorazepate. Pump
system revised. Patient subsequently
deferevesced and tone returned to
baseline.
Kao et al. [4] 4 M Cerebral Palsy Pump noted to be
empty and beeping.
Time to onset
unknown.
Dystonia, Pyrexia (42.1°C), Tachycardia,
Tachypnoea, Hypertension, Reduced O2
Saturation, Wheeze, Crepitations,
Leukocytosis
Admitted to PICU. Paracetamol and
bronchodilators. Following pump refill,
fever and tachycardia resolved over four
to eight hours. Recovery.
Salazar et al.
[13]
14 M Cerebral Palsy Less than 1 mL left in
pump reservoir
Dystonia, Rhabdomyolysis (2500 IU/L),
Tachycardia, Agitation, Hypertension,
Diaphoresis, Haematemesis, Melaena,
Clotting Derangement, Transaminase
Elevation
Pump refilled. Diazepam and
cyproheptadine used to control tone.
Discharged on hospital day four.
Saveika et al.
[14]
14 F Cerebral Palsy Pump Stall 8 hrs
previously
Dystonia, Pyrexia (37.8°C), Tachycardia,
Agitation, Pruritis
Oral baclofen and cyproheptadine.
Recovery within 24 hours.
Alden et al.
[5]
14 M
Adrenoleukodystrophy
Catheter failure 1
week following spinal
surgery
Dystonia, Pyrexia (40°C), Tachypnoea IV lorazepam and oral baclofen. Pump
and catheter revision. Discharged on
post-operative day two.
Zuckerbraun
et al. [15]
7 F Traumatic Brain
Injury
Due for refill the
following day
Dystonia, Pyrexia (40.8°C), Tachycardia,
Impaired Consciousness, Tachypnoea,
Diaphoresis, Seizure, Leukocytosis
Baclofen bolus and pump refill.
Defervesced over four hours.
Zuckerbraun
et al. [15]
14 M Traumatic Brain
Injury
ITB catheter
disconnection. Time
to onset unknown.
Dystonia, Pyrexia (41°C), Tachycardia,
Agitation, Hypotension
Four day admission. Misdiagnosed with
viral illness and discharged. Withdrawal
episode diagnosed on the basis of a
subsequently identified catheter
disconnection. Catheter subsequently
revised with an improvement in tone.
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this constellation of symptoms does not exclude the
possibility that the patient is experiencing an episode of
SD coincidentally. In one third of the cases reviewed,
the time of the presumed causative system failure was
unknown. ITB infusion systems frequently fail and it is
possible that these had failed previously and that this
was only identified during an unrelated subsequent epi-
sode of SD. Indeed, there is one case report in the adult
literature in which no evidence for ITB pump failure is
ever identified but “intermittent pump stall” is postu-
lated solely on the basis of the patient’s clinical presen-
tation [8]. Caution should be exercised when attributing
complications to ITB withdrawal in the absence of a
direct temporal relationship between the onset of symp-
toms and ITB infusion system failure.
Second, the similarity between this episode of SD and
the complications attributed to ITB highlights the possi-
bility that the complications witnessed in episodes of
ITB withdrawal may be instances of SD. Abrupt with-
drawal of both lithium and tetrabenazine have pre-
viously been implicated in precipitating SD [9], and
abrupt withdrawal of ITB may have a similar effect. If
so, this would have significant implications both for the
management of complications associated with ITB infu-
sion and for the perceived risks associated with the pla-
cement of an ITB infusion system.
Conclusion
We have presented a case of status dystonicus with fea-
tures comparable to those attributed to ITB withdrawal;
the case serves as a caution against over-diagnosing ITB
withdrawal syndrome and highlights the possibility that,
the complications observed in “ITB withdrawal syn-
drome,” and exceptionally rarely associated with oral
baclofen withdrawal, may themselves be an instance of
status dystonicus precipitated by the drug’s withdrawal.
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